Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs

Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs

Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk. The post Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs appeared first on MedCity News.

Alveus launches with $160M to advance MariTide-like obesity drug

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.

Alveus debuts in obesity arena with $160m Series A - Pharmaceutical Technology

Alveus will use the funds to support a Phase II trial and progress more assets towards to the clinic.

Obesity biotech Alveus gains $160M for push into MariTide's backyard — and amylins

Another obesity biotech has entered the fray as tirzepatide and semaglutide fly off pharmacy shelves. Alveus Therapeutics disclosed a $159.8 million Series A on Thursday morning to create medicines that drive better quality of weight ...